Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice

Background: In clinical studies, some patients who achieve deep molecular response (DMR) can successfully discontinue tyrosine kinase inhibitor (TKI). TKI dose reduction is also an important aspect of alleviating adverse effects and improving quality of life. This study aimed to explore the outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yilin, Zhao, Huifang, Guo, Jingming, Zou, Jing, He, Wenjuan, Han, Danlei, Cheng, Fanjun, Zhang, Yanli, Li, Weiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899816/
https://www.ncbi.nlm.nih.gov/pubmed/36755944
http://dx.doi.org/10.3389/fphar.2023.1101743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899816/
https://www.ncbi.nlm.nih.gov/pubmed/36755944
http://dx.doi.org/10.3389/fphar.2023.1101743

Ejemplares similares